Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Post-contracture Release Radiation for Dupuytren's Disease

Study ID: NCT04122313
Start Date: 2019-05-31
End Date: 2026-03-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Evaluation of Dupuytren's Disease Treatment

Sponsor

The University of Minnesota

Source: clinicaltrials.gov

Share:
Add to list

Niraparib in Tumors Metastatic to the CNS

Study ID: NCT04992013
Start Date: 2022-04-05
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Nirparb

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Study ID: NCT04299113
Start Date: 2020-05-14
End Date: 2026-05-22
Study Type

Interventional

Study Phase

Phase1

No. of Participants

38

Intervention / Treatment

Vinorelbine

Mocetinostat

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Study ID: NCT03191149
Start Date: 2018-04-25
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

46

Intervention / Treatment

Biospecimen Collection

Computed Tomography with Contrast

Echocardiography Test

Magnetic Resonance Imaging

Multigated Acquisition Scan

Osimertinib

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Study ID: NCT05480449
Start Date: 2022-09-20
End Date: 2029-09-20
Study Type

Interventional

Study Phase

Phase2

No. of Participants

89

Intervention / Treatment

Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

Sponsor

Stephan Grupp MD PhD

Source: clinicaltrials.gov

Share:
Add to list

Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions

Study ID: NCT06463249
Start Date: 2024-06-17
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

CORE Helpline

Extended Helpline

Enhanced Helpline

Intensive Helpline

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Study ID: NCT05808634
Start Date: 2023-07-14
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

168

Intervention / Treatment

He sold 182

Sponsor

Bioatla, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Study ID: NCT03165734
Start Date: 2017-06-26
End Date: 2027-07-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

399

Intervention / Treatment

Pacritinib

Physician's Choice medications

Sponsor

Swedish Orphan Biovitrum

Source: clinicaltrials.gov

Share:
Add to list

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

Study ID: NCT05930496
Start Date: 2025-06-21
End Date: 2025-10-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Biospecimen Collection

Exercise Intervention

Exercise Intervention

Health Education

Interview

Administration questionnaire

Sponsor

Fred Hutchinson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Study ID: NCT04576117
Start Date: 2021-02-16
End Date: 2026-12-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

300

Intervention / Treatment

Biospecimen Collection

Magnetic Resonance Imaging

Quality-of-Life Assessment

Administration questionnaire

Selumetinib Sulfate

Vinblastine Sulfate

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list